A biotechnology company had brought their lead compound successfully through Phase 2 trials for a very rare endocrine disorder.  We helped them understand how their target clinicians would react to the existing data, and how best to generate compelling endpoints and measurements going forward.

A large global pharmaceutical company had identified auto-immune disorders as key targets for their R&D organization.  We conducted a Multi-Variable Analysis of a range of auto-immune diseases to evaluate opportunities while remaining product agnostic.

A large pharmaceutical company in partnership with a leading biologics company were preparing for the launch of a blockbuster monoclonal antibody in immunology.  They had full development programs for two indications in place, but felt the compound could address a variety of additional indications.  We conducted a Multi-Variable Analysis to recommend disease areas that provided opportunity and fit with this biologic.

A biotechnology company was looking to develop compounds for acute myloid leukemia, but had limited internal resources to evaluate the market.  We conducted a Market Opportunity Map to identify unmet needs and enhance their early stage decision making.

A large pharmaceutical company had a series of compounds with potential for treatment in prostate cancer.  They asked us to produce a Market Opportunity Map to highlight the various opportunities in this market and allow them to tailor their development programs and sequence their launches appropriately.

A mid-sized biotechnology company had a portfolio of products all focused on orphan diseases.  They wanted to provide access to all patients around the globe, and asked us to evaluate the market access processes not only in leading industrialized markets, but across all countries where there might be significant patient need.